

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

Assignment ID: PATI144074

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
PROTEIN POTENTIAL, LLC	04/03/2024
RECEIVING PARTY DATA	
Company Name:	SANARIA INC
Street Address:	9800 MEDICAL CENTER DRIVE
Internal Address:	A-209
City:	ROCKVILLE
State/Country:	MARYLAND
Postal Code:	20850
PROPERTY NUMBERS Total: 9	
Property Type	Number
Application Number:	62189083
Application Number:	17660558
Application Number:	60748779
Application Number:	63133131
Application Number:	17566901
Patent Number:	10695415
Patent Number:	11324814
Patent Number:	7749519
PCT Number:	US1641192
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	5106856405
Email:	ddolberg@sanaria.com
Correspondent Name:	Dr. david Dolberg Esq
Address Line 1:	37 Terrace Ave
Address Line 4:	Richmond, CALIFORNIA 94801
ATTORNEY DOCKET NUMBER:	SAN000

NAME OF SUBMITTER:	David Dolberg
SIGNATURE:	David Dolberg
DATE SIGNED:	04/04/2024
	This document serves as an Oath/Declaration (37 CFR 1.63).
Total Attachments: 3 source=PP-SANARIA ASSIGNMENT#page1.tif source=PP-SANARIA ASSIGNMENT#page2.tif source=PP-SANARIA ASSIGNMENT#page3.tif	

INTELLECTUAL PROPERTY ASSIGNMENT

In consideration of the sum of \$1 (One dollar) or equivalent and other good and valuable consideration paid to **Protein Potential, LLC**, a corporation formed under the laws of Maryland, whose mailing address is 9800 Medical Center Drive, Suite A209, Rockville, Maryland 20850 (hereafter referred to as the “**Assignor**”), Assignor does hereby sell and assign to, **Sanaria Inc.**, a corporation formed under the laws of Maryland, whose mailing address is 9800 Medical Center Drive, Suite A209, Rockville, Maryland 20850 (hereafter referred to as the “**Assignee**”), its entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world, along with any and all incumbrances attached thereto:

- (a) in the invention(s) known as **LIVE ATTENUATED ORAL VACCINE AGAINST SHIGELLOSIS AND TYPHOID FEVER**, for which: i) a provisional application for patent in the United States of America was filed on July 06, 2015 (also known as **US Serial No. 62/189083**); ii) a U.S. non-provisional patent (**US Patent No: 10,695,415**) was issued on June 30, 2020; iii) a U.S. divisional patent (**US Patent No: 11,324,814**) was issued on May 10, 2022; and iv) a second US divisional application (**US Serial Number 17/660,558**) is pending, and in any and all non-provisional applications and patents issued therefrom; and in foreign filed patents and applications, including but not limited to: i) **Patent Cooperation Treaty Application No. PCT/US 2016/041192**; ii) **European Patent Application No: EP16821934.3**; iii) Indian Patent Application No: **2018/17001327**; iv) **Hong Kong Application No: 18114545.1**; and v) **Israeli Patent No: 256729**, issued on February 2, 2023, and in any and all Letters Patent(s) granted from such foreign filed applications; and
- (b) in the invention(s) known as **UNIQUE DNA AND POLYPEPTIDE SEQUENCES BASED ON THE CIRCUMSPOROZOITE PROTEIN OF PLASMODIUM VIVAX** for which: a provisional application for patent in the United States of America was filed on December 9, 2005 (also known as **US Serial No. 60/748,779**), and a U.S. non-provisional patent (**US Patent No: 7,749,519**) was issued on July 6, 2010, and in any and all Letters Patent(s) granted from such non-provisional applications; and
- (c) in the invention(s) known as **LIVE ATTENUATED ORAL VACCINE AGAINST COVID 19** for which a provisional application for patent in the United States of America was filed on December 31, 2020 (also known as **US Serial No. 63/133,131**); and a non-provisional application (**USSN 17/566,901**) is pending, and in any and all Letters Patent(s) granted from such non-provisional applications; and
- (d) in any and all applications that claim the benefit of the patent application listed above in parts (a-c), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in parts (a-c), to the full extent of the term or terms for which Letters Patents issue, and

- (e) in any and all inventions described in the patent application listed above in parts (a-c), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;
- (f) all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The Assignor agrees to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The Assignor agrees to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The Assignor hereby grants the patent practitioners associated with **CUSTOMER NUMBER 78260** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The Assignor hereby represent that it understands that the patent practitioners associated with **CUSTOMER NUMBER 78260** are the legal representatives of, and attorneys for, both the Assignor and Assignee and hereby waives all rights with regard to conflict of interest in favor of Assignee.

IN WITNESS WHEREOF, executed by:

Protein Potential, LLC (Assignor)

KimLeeSim 04/03/
B. Kim Lee Sim, PhD Date
President and Chief Scientific Officer

Sanaria Inc. (Assignee)

Stephen Hoffman 04/03/
Stephen Hoffman (Apr 3, 2024 21:17 EDT)
Stephen L. Hoffman, MD Date
Chief Executive and Scientific Officer









doc.2024.0311.IP.Assignment

Final Audit Report

2024-04-04

Created:	2024-04-03
By:	Alexander Hoffman (costarajah@yahoo.com)
Status:	Signed
Transaction ID:	CBJCHBCAABAA5LtAliqplu33MXqXJOpy5PUA0Lyz8j9D

"doc.2024.0311.IP.Assignment" History

-  Document created by Alexander Hoffman (costarajah@yahoo.com)
2024-04-03 - 9:27:34 PM GMT
-  Document emailed to Kim Lee Sim (ksim@sanaria.com) for signature
2024-04-03 - 9:27:38 PM GMT
-  Document emailed to Stephen Hoffman (slhoffman@sanaria.com) for signature
2024-04-03 - 9:27:38 PM GMT
-  Email viewed by Kim Lee Sim (ksim@sanaria.com)
2024-04-03 - 9:36:11 PM GMT
-  Document e-signed by Kim Lee Sim (ksim@sanaria.com)
Signature Date: 2024-04-03 - 9:38:58 PM GMT - Time Source: server
-  Email viewed by Stephen Hoffman (slhoffman@sanaria.com)
2024-04-04 - 1:16:57 AM GMT
-  Document e-signed by Stephen Hoffman (slhoffman@sanaria.com)
Signature Date: 2024-04-04 - 1:17:49 AM GMT - Time Source: server
-  Agreement completed.
2024-04-04 - 1:17:49 AM GMT